Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Xbrane Biopharma, Pressconference, 2024

By Inderes4/22/2024, 12:00 PM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin Åmark
00:00 - 01:14

So good. Good afternoon, everyone, and welcome to Xbrane Biopharma AB's webcast regarding the FDA review and the press release we published yesterday. My name is Anette Lindqvist and I'm the CFO, having joined the team in 2021. Sorry. With us today. We have two members of the board. We have Anders Tullgren, our chairman of the board since 2018, and we've also Kirsti Gjellan, who joined the board in 2022 and contributes first and foremost with vast manufacturing and quality experience. I also would like to present three colleagues of mine, David Vikström, our Chief Technology Officer and also head of R&D, and Anders Wallström, our head of manufacturing and supply chain. Last but not least, our CEO, Martin Åmark. Following a brief presentation, there will be a Q&A for which you can ask questions in writing throughout the presentation. And by that, I would like to give the word to Martin. Please, Martin. Go ahead.

Anders Tullgren
01:16 - 05:04

Thank you, Anette. And so, I first wanted to go through the history of our Biologics License Application, also called BLA, for our biosimilar candidate under the development name Xlucane. It was submitted in April last year, and the FDA took a so-called filing decision in June 2023, and the review process of the BLA was then started. Um, and a basis for that, that is to say, a goal date or a decision date was set to April 21st, 2024. So that is the date, uh, when the FDA, according to the dictated process, needs to take action, a decision either to approve the application or to, um, postpone the date or issue a so-called Complete Response Letter we had during the review process. Um, as is dictated by the process, both mid-cycle and late-cycle review meetings with the FDA in October and January 2024, respectively, uh, where no major issues were at that point in time. Uh identified um, as is part of um, review processes, uh, for approval in the US, um, you typically conduct so-called pre-approval inspections at the manufacturing sites involved and proposed to produce the product for commercial supply to the US that took place, uh, even for this review process in January and February this year, respectively. Um, and, uh. In those inspections. There were observations from the FDA, which you then typically have a three-week response time on, and the respective sites responded to the FDA within that timeframe. And we also received, of course, numerous different information requests from the FDA on the application itself throughout the whole review process, which were responded to in time. So, um. Friday evening US time, that is to say, 19th of April. Um, we received a so-called Complete Response Letter from the FDA. Um, and it contained, uh, two main, um, deficiencies in relation to the application, which, according to the FDA, needed to be resolved in order for them to be able to approve, uh, the application. The first one was related to, um, the so-called reference standard to be used for release of the product to the US market. And I'm here going to hand over to David to elaborate a little bit further on this specific, uh, deficiency identified or stated by the FDA.

Kirsti Gjellan
05:04 - 06:50

Yes. Thank you very much, Martin. So, um, this is David Vikström speaking. Um, uh, CTO of Xbrane. And as Martin mentioned, we have a reference standard in the Xlucane exchange program. And this reference standard, it's qualified with several different analytical methods. And the reference standard is used to compare a newly produced batch to be certain that it can be released to the market. And during the FDA review process, the FDA requested a new, tighter specification on one of the methods used in the qualification of the reference standard. And to solve this issue, we have created a task force. And this task force is made up of very experienced team members, both from Xbrane Biopharma AB, but also external expertise. We are certain to solve this issue. We basically started looking into this immediately and I would say already now we have identified a good way forward, and are working on it. Creating the plans. Exactly how to solve this. And we will also ask the FDA for a meeting. To be certain, then, that the FDA agrees with our solution to this issue. Handing back to Martin mark.

Anders Tullgren
06:51 - 07:26

Thank you. And so as David Vikström said, this is an issue we are confident in being able to resolve and provide a satisfactory response to the FDA. On the other deficiencies stated by the FDA was related to the inspections on our contract manufacturers' production sites. So on this topic, I would like to hand over to our head of manufacturing and supply chain. And just to elaborate a little bit further.

Anders Wallström
07:26 - 07:27

Thank you. Martin mark.

Unknown
07:28 - 10:10

Yeah. So these pre-approval inspections, as mentioned earlier this year, we have prepared for them since a long time back together with the different manufacturers. So we have included external support, expert support. We have used what's called mock inspections with former FDA inspectors in order to ensure that quality systems and processes are in place, to a standard which can be accepted by the FDA. And we have worked through those improvements identified earlier on to make sure that we would be able to make those then the pre-approval inspections were conducted by the FDA beginning of this year. They were completed as planned by the FDA. And there were observations mentioned by the FDA at both sites. And the observation is nothing out of the ordinary. It's, according to my experience, very normal and expected to receive observations as an outcome of a pre-approval inspection. So, what happens next is that the sites prepare responses to any observation and this was done by both sites, and they were submitted on time. These responses include comprehensive action plans to improve on those areas where the FDA had highlighted concerns or deficiencies. So we are of course already, since the inspection, working on completing these actions together with the manufacturers. What can be mentioned here is that the pre-approval inspections were conducted very late in the FDA review procedure we took in January and February. So the responses were submitted three weeks after inspection, and that's not so long ago. So now with the complete response letter, it is in itself not specific on which of the actions proposed by the manufacturers are not sufficient, according to the FDA to close those observations. So we are in contact with our manufacturers and we will work together with them, continue to work together with them, including requesting meetings with the FDA here to clarify if there is something missing in this action or if any additional actions are required by the FDA. Yeah, we have an experienced team both here to explain with our board, but also with our partner startup to support the manufacturers. And we will do that together with the manufacturers to close out all observations. I would like to hand over to Anette Lindqvist here to comment, maybe based on your experience as well in this area.

Anette Lindqvist
10:11 - 12:46

Thank you, Andy. So, as Anette Lindqvist already mentioned, I joined the board of Xbrane in May 2022, in a time where the pre-approval inspection preparations were already accelerated in close collaboration with the manufacturing contractors, and building on the work with tech transfers, scale-up, and validating commercial processes. As you all know, and based on my own experience as head of quality and head of internal and external manufacturing in different companies, working with the FDA is an extensive journey of compiling data, content, and evidence to support the regulatory requirements of safety, efficacy, and security for the patients. FDA inspections not having Form 483 observations are rare, and the team has worked diligently to respond to the FDA observations, delivering on time to the FDA. Through the whole process of providing content to the BLA and where we are today. Given the fact that we now, unfortunately, have received a Complete Response Letter. We are, obviously, as one organization, including the board, working with the FDA, leveraging our strong relations with our contract manufacturers and relevant supporting expertise to close the CRL. I think all of you also have noticed that Complete Response Letters are seen in the pharmaceutical industry, both in small and larger companies. The FDA has the process in place to continue to work with the applicants to work through the CRL, a process that experiments data is starting to close the remaining gaps in collaboration with the manufacturers and other relevant competencies. Um, and this will be done as soon as possible, starting with requesting meetings with the FDA on the different areas. According to what our CEO, Martin Åmark, just mentioned. So, please, Martin, do you want to continue?

Anders Tullgren
12:48 - 13:01

Yes. And handing over maybe to our chairman, Anders Tullgren, who also is online to elaborate a little bit on elements where the FDA actually did not request additional information.

Kirsti Gjellan
13:02 - 13:04

Thank you very much, Martin.

Unknown
13:04 - 14:56

And as told again here. I, chairman of the board since 2018, have formerly worked many years globally with more than 15 different launches of new products around the world. And I would say in most of them, we had always some issues with the FDA we had to work with. So this is very much what is quite common when you work with the FDA; there are different things. Let us also put this in perspective, because with this response, we actually got some clarity. We got some clarity on where the FDA did not have any questions. So they have accepted our clinical trial. And as you remember, for biosimilars, we need to compare ourselves with the original product. And we did a clinical trial with more than 600 patients for over three years. And, that there has been no request for on that and that has been accepted by the FDA. So I think that's very important. We also have studies that demonstrate biosimilarity. And also there, there were no questions from it. So I think when we look at the whole FDA package, it's a huge package. But now we have clarity on the parts of the package which have been accepted by the FDA. And to date, we have also not received any request for reinspection. So, of course, we are disappointed that we received this Complete Response Letter. But as the team has said, we are working together on these issues and we need to get more information back from the FDA on this and then work on a timeline and action plan after that. But we also have to remember that there are significant parts of this file which have also been accepted by the FDA. So with that, I hand it back to you, Martin.

Anders Tullgren
14:58 - 16:21

Thank you. So, with regards to the path forward from here towards the resubmission of the BLA and eventual approval, we are going, as we have discussed in this call, to request meetings with the FDA to clarify further this deficiency stated and make sure that we are responding to them in an adequate way when we resubmit the BLA, according to guidelines. The FDA is required to grant such meetings within 30 days from the request. And we really need to have these meetings before we can provide a planned date for resubmission. And as soon as we've been able to have these meetings and as soon as we've decided on a new submission date, we will communicate with the market to clarify that. So that was the formal presentation. And we are then going to go into Q&A. So, over to you on it.

Martin Åmark
16:21 - 16:46

Well, thank you, Martin. Yes. Uh, I can see there are already quite a few questions and one of the key messages is obviously around the timelines and how much delay we can expect. So, if you can elaborate a bit on that, because there are several questions regarding this and also how confident you are in terms of receiving final approval from the FDA.

Anders Tullgren
16:47 - 17:38

Yeah. So, with regards to the timing, as I just said, we are not going to be able to comment on that. As of now. We really need to have these clarifying meetings with the FDA first before we decide on the timing of resubmission. So we ask for patience until we can get back to the market on that point where we have decided. I think, though, as Anders alluded to, there were things which were not mentioned as issues in our application. And I think in that also, we can conclude, actually, that the probability of final approval has increased, although we are evidently facing a delay. Yes.

Martin Åmark
17:38 - 17:55

Yes, yes. Thank you. So, the next question is who's responsible within the company for the application to the FDA. And I was thinking then, you know, we have worked with external consultants for this as well. Martin.

Anders Tullgren
17:56 - 18:43

Yeah, I can answer that. Yes, of course, I am. As the CEO of the company, I am ultimately responsible for the application of this program to the FDA and eventual approval. And organizationally, we are working with different functional heads representing R&D, as David joined in this call on the supply side, but also functional heads within regulatory and so on. And therefore, in these functions, there are subject matter experts responsible for different parts of the application. But of course, needless to say, I am the overall responsible for making this a success.

Martin Åmark
18:44 - 18:58

So the next theme among the questions is the partner for the US and a potential launch in the US. So could you elaborate a bit on this?

Anders Tullgren
19:00 - 20:07

Yes, we have, as everybody knows, and we've talked about being in the process of securing a commercialization partner for the US market. That process is far advanced. We're in the final stage of contract negotiation. However, needless to say, I think that everybody on this call understands this. We now, since we received the Complete Response Letter over the weekend, need to review this with the potential commercialization partner and see what potential implications that might have for this potential upcoming deal or collaboration. So, this is also a question we really hope that we're going to be able to get back to you all around in the near term future with positive news, but we really need to keep it at that and have those discussions during the coming weeks.

Martin Åmark
20:09 - 20:16

Yeah. Is there any news around this, the FDA news, whether this is a class one or class two resubmission?

Anders Tullgren
20:18 - 20:43

Yes. So I think we had this question before coming in over emails as well. And I think that this class one and class two categorization is related to medical devices. What this is going to be classified as is a resubmitted BLA, for which there is a formal guideline and process within the FDA.

Martin Åmark
20:45 - 20:54

And can you say anything around this? You know, this. How long that could take? Normally after the resubmission.

Anders Tullgren
20:55 - 21:19

Our understanding is that according to the guideline, it's a six-month review process by the FDA for a resubmitted BLA. However, we've also seen approvals coming through or conclusions coming through out of such a process within a shorter timeframe. But according to the guideline, a six-month review process.

Martin Åmark
21:22 - 21:37

Okay, so moving on to our financial targets. So, a question on our earlier communicated view of becoming cash flow positive in Q1 2025.

Unknown
21:39 - 21:39

Yeah.

Anders Tullgren
21:39 - 21:46

So maybe here I can hand over to this tool to elaborate a bit on this question.

Unknown
21:47 - 25:41

Thanks, Martin. And perhaps you can come back later, I think. I think what we need to do as well is to put this in perspective. Of course, we are not a one-product, one-country company, but we actually have, I would say, five different legs or five different opportunities, all of them with a lot of long-term value. The first one is, of course, execution in the FDA, and we have now got some clarity on that. And we need to work very fast to resolve those issues and launch in the US market. And we, as Martin said, will come back with information about that after the meeting with the FDA. The second leg we have, the second opportunity we have is actually that we are on the market in Europe. We are selling our product in 15 countries in Europe. And we will continue to do that with our partners' data. And we see growth here and we see the sales uptake. So, we are in a commercial phase with our company. And we see the sales picking up there through our commercial partners' data. The third thing is our product. And is that a biosimilar of Simca. And that project is ongoing and according to plan. And we hope to go into a clinical phase next year together with our partner Biogen. And that's progressing very nicely. And the same product has fantastic potential. It is actually a very difficult product to produce. And, thanks to our patented technology, we are, from what we know and what we have seen, The only biosimilar company that's been able to do a biosimilar of this product, and this product's original sales are about 2 billion US dollars. So it's a big product. So that's a product with very big potential and long-term value. And has also created a lot of interest because we have been able to develop this biosimilar. The fourth one is a biosimilar of Opdivo, a product I know very well since I was part of the launch of that product around the world when I worked for Bristol-Myers Squibb. And here this is also progressing as planned internally, we are looking for the right commercial partner for that product and that work is ongoing and accelerated and, of course, here it's a huge opportunity. It's already now with very high sales of immuno-oncology products, and we foresee them to be even bigger when the patent expires. So that's a huge opportunity. And that's the fourth opportunity we have with a lot of long-term value. And the fifth opportunity we have is actually our platform technology, our patent. We have several patents around this unique portfolio platform and also the portfolio where we have the capacity of doing one new biosimilar per year. And that also adds a lot of value to that patented technology. So I think we are disappointed with the recent setback with the FDA. But I think we need to remember as well that we have five different opportunities. And we, of course, also from a financing point of view, are looking at how to work with all of these five opportunities to secure our financing going forward. And with that, perhaps, Martin, you can talk a bit more about the financing.

Anders Tullgren
25:43 - 26:53

Yeah, exactly. We are going to continue to work intensively to capitalize on our different programs and opportunities as laid out. Um, on the one hand, under established, uh, partnerships, which we have with, um, Sandoz and Biogen, uh, for, uh, um, Xlucane and, uh, other biosimilar candidates, respectively. We are also going to work intensively to establish new partnerships, as we already talked about for, um, um, Xlucane as our lead biosimilar candidate in the US, but also to, to tie up, uh, development and commercialization partners for Xlucane and other biosimilar candidates. Um, so we're going to work intensively on all these fronts. And then also, as we've talked about throughout this call, uh, we need to get clarification about the extent of the delay we are facing with regards to the first leg, if you will, FDA approval and eventual US market launch of, uh, of, uh, Xlucane.

Unknown
26:54 - 26:54

Um.

Anders Tullgren
26:55 - 27:08

So all this will dictate, um, um, uh, financing needs and the timing of getting to positive cash flow. And also these questions, given all we've talked about, we need to get back on.

Unknown
27:09 - 27:09

Um.

Martin Åmark
27:11 - 27:20

Uh, there's one question related to this around the current sales. Uh, so how are we doing in Europe with Xlucane.

Anders Tullgren
27:23 - 27:39

Uh, well, uh, we are going to, uh, release the Q1 report later in May. And, uh, this is a question we need to defer to that point in time. And the related webcast, uh, uh, for the Q1 report.

Martin Åmark
27:42 - 28:09

Yep, yep. Thank you. So, uh, just glancing through the questions here. Um. Can you elaborate a bit on how are these issues raised by the FDA? Different from what happened when we withdrew our first application? In 2022. How is this different?

Unknown
28:10 - 28:10

Yeah.

Anders Tullgren
28:11 - 28:11

Well.

Unknown
28:13 - 28:13

Um.

Anders Tullgren
28:14 - 29:20

When you submit a BLA, um, to the FDA, the first thing that happens is that the FDA goes through a so-called validation process where they essentially check the application for completeness. Um, is everything in there that needs to be in there for us to conduct a review process? That is what they're trying to sort out in the first two months. That is what happened the first time we submitted a BLA, that there were a few information gaps, uh, which according to the FDA, um, made it not possible for them to conduct the review and hence, uh, they couldn't take a filing decision, and we needed to withdraw the file, withdraw the file, and, um, um, complete the application, uh, with these information gaps stated. Uh, but none of these, um, information gaps which relate to the field are now subject to the recently received a complete response letter.

Unknown
29:21 - 29:21

Mm.

Martin Åmark
29:24 - 29:38

Nice. One quick question from Felipe Anderson. Uh, do you consider the timeline for Albert's CRL for its biosimilars to be similar, relevant for investors to consider when evaluating the expected timeline for a similar process?

Anders Tullgren
29:40 - 30:20

I don't think we should get into speculation, uh, with regards to our specific situation and our CRL recently received and, um, similar processes that other companies have gone through, I think we should stick to what we already have. Members have mentioned in this call that we need to have these initial meetings with the FDA to get clarification and alignment around our response strategies for these different questions and then get back with the first timing of resubmission and also envision review timeline.

Unknown
30:21 - 30:21

Um.

Martin Åmark
30:23 - 30:28

Does this sale have any impact on the Biogen cooperation?

Anders Tullgren
30:29 - 30:31

Short answer is no.

Martin Åmark
30:33 - 30:41

Yes. And are the deviations stated in the serial by any means connected to the prefilled syringe presentation?

Unknown
30:42 - 30:42

No.

Unknown
30:43 - 30:44

Um. They're not.

Martin Åmark
30:46 - 30:57

Yes. Is there a scenario where Xbrane could finalize the execution of licensing partnerships without formal FDA approval?

Anders Tullgren
30:59 - 31:28

Of course. As those of you who have followed us for some time Remember, we signed a license deal with Bausch and Lomb for the intended commercialization of this same biosimilar candidate long before we even submitted a BLA. And such license arrangements typically take place before approval. So, that's nothing uncommon at all.

Martin Åmark
31:30 - 31:57

Yes. A bit on the cost base throughout 2024, will there be any expected cost base, as we have communicated earlier, that will shift somewhat in 2024. Are there any implications from yesterday's news on how the cost base will change and how that could be expected?

Anders Tullgren
31:59 - 32:24

I think maybe this question is related to the cost reduction program. We launched and communicated around in November last year, and that is being implemented according to plan. And we envision to realize the savings as previously communicated.

Martin Åmark
32:25 - 33:05

Yes. And I could just chip in on this, that is something that we have been following closely. It has been now fully executed. And we will communicate the first insights on those when we communicate the Q1 report at the end of May or mid-May. So, a bit round. What's so unique? Maybe this. If you would like to comment, there's a question. How is Xbrane different from its competitors? And how do you see the prospect for the company?

Unknown
33:07 - 34:35

Yes, we are the only biosimilar global developer in the Nordic countries. So we are quite unique in that regard. And I think, going forward, we know that the biosimilar market will be the fastest-growing market segment in the pharma industry. So we are, in that case, quite a unique company. There are, of course, other biosimilar developers globally. But for the Nordic countries, we are unique. And I think what makes us unique as well is our patented technology. We have a very good team of scientists who have developed this technology, and we've been able to patent it. So I think that is where it stands out. I mean, you need to be unique in something. And I think our core competence in drug development of biologic products is actually our biggest core competence. And perhaps, David, you can just briefly talk a little bit about what you are doing from a research point of view and also a little bit on the things we have been able to patent that I think differentiate us from a lot of other biosimilar or biologic companies. So perhaps, David, can I ask you to say something briefly about that?

Kirsti Gjellan
34:36 - 36:54

Absolutely. So I think. One thing that is really important is to have the expertise in-house. Quite a number of smaller companies rely heavily only on service providers when it comes to development and expertise. We have a great team here in Solna, of about 70 people. We have really unique expertise and competencies. I would say it's really a great team to work with, where everybody really makes each other better. When it comes to equipment, we have almost 2000m² of lab space, which means that we can really develop and solve very complex problems. And this is also one of the reasons why we have managed with such a difficult substance as Xlucane, and managed to take that from basically nothing all the way up to the scale-up stage. It's a very, very complicated molecule. And that's why we are alone with that biosimilar. When it comes to more expertise that we have. We're working both with bacteria and also with mammalian cells, and we are working to make the cells better, both from a quality perspective and also from a yield perspective. So we're working with the cells and we're working with the blueprint that the cells are using to produce our biosimilar of interest. And when we talk to our collaboration partners, but also when we discuss with our competitors, which happens every now and then, we can really see that we have a technology edge when it comes to this, we can solve problems that others have a lot of difficulties with. And we can also.

Unknown
36:55 - 36:56

Um.

Kirsti Gjellan
36:57 - 37:25

Really produce new things that others cannot. And again, this comes back to us being able to get patents on our technology because if our technology was not new and inventive and could really be used, we would not get these patents. So we currently have 15 patents and 50 patent applications. So I can talk forever.

Unknown
37:25 - 37:57

So I don't think we have time for that, David. But I think it was important to put the perspective because I think sometimes we are actually not communicating the very strong scientific basis that this company is built on. And that is really what is unique. Also, if we compare ourselves with all global competitors that are also in the biosimilar biologic space. So thank you, Anette. With that, I hand it back to you. Yeah.

Martin Åmark
37:57 - 38:23

So, no thanks. Anders and David, um, I think there's an interesting question, David, that you might want to elaborate a bit further on linked to this, um, explain in the future, how do you see the opportunity to collaborate with others and be partners with other developers of biosimilars and actually, um, make their production much more efficient using our technology? Is that something that we are looking into?

Kirsti Gjellan
38:26 - 39:09

Uh, well, yes, I would like to say yes. We have discussions, I mean, I can't go in depth, of course, but, you know, during conferences, etc., during different interactions with other companies, we are always investigating these opportunities on how we can use our platforms to make other companies, both big and small, their platform, their technology or their process, more efficient using our platform and our technologies. So, I would say, absolutely. There is an opportunity there.

Martin Åmark
39:12 - 39:39

Thank you, David. Um, there are quite a few questions coming in. Solid around the financing position. Additionally, if the FDA requirements necessitate taking in more capital. And so, Martin, do you want to say anything further? There's also one question around our target to become cash flow positive in Q1. Uh, and the the.

Anders Tullgren
39:40 - 40:38

Yeah, I think we, uh, I think we answered that question before, and I think what we also stated very clearly in the prospectus of the recently conducted rights issue and the communication around that, uh, that the proceeds from that, uh, rights issue, uh, would take us to Q1 2025, provided that we met a couple of very important milestones throughout the year, out of which one was the FDA approval of, um, Xlucane biosimilar candidate. So, in light of this recently received Complete Response Letter, we need to look back and understand what this means. Overall, for our financial position and timing of reaching positive cash flow. But, as I said earlier as well, we are working very actively to capitalize on all of our programs. And this is not the only source of income for us during the course of the year.

Unknown
40:39 - 40:39

Um.

Martin Åmark
40:40 - 40:50

How far has your next biosimilar reached in the development phase? And when could we expect that to be launched to market?

Anders Tullgren
40:54 - 41:20

And the next one after exclusion is debate. One sees a biosimilar candidate which is currently going through the scale-up, a scale-up process, and production of clinical material, which then, under the collaboration with Biogen, is then going to be their responsibility to take the product further into the clinic.

Martin Åmark
41:23 - 41:32

Is there anything we know about the queries related to your manufacturing partner and clarity on the timeline for this process?

Unknown
41:37 - 41:37

Um.

Anders Tullgren
41:38 - 42:28

I think we need again to have these clarifying meetings with the FDA as the Complete Response Letter in this respect was rather generic due to the confidentiality undertakings between actually the FDA and our contract manufacturers. And we need to have these meetings with the FDA and with our contract manufacturers to understand more in detail which observations and related proposed actions and improvements by the sites are subject to FDA making an assessment that this application was not approvable at this time. And only after we've had those interactions, we can get back with further clarity. Yes.

Martin Åmark
42:29 - 42:46

I was quite impressed that there were only two findings by the FDA and that all clinical data were considered sufficient to consider the FDA response, essentially as quite positive for the long-term development of the company.

Anders Tullgren
42:49 - 43:14

As I said, if I may comment, I think. The probability of approval has increased. However, we are facing a delay. Of course, if there had been a Complete Response Letter stating that additional clinical trials were required. That would have been a challenge for us. Both, of course, from a financial implication perspective and from a timing perspective.

Unknown
43:15 - 43:15

Yes.

Martin Åmark
43:16 - 43:21

So, do we know if there's going to be a new BsUFA date this year or not?

Anders Tullgren
43:23 - 43:28

You know, as we've alluded to and talked about in this call, this is the question we need to get back to.

Martin Åmark
43:30 - 43:38

Yes. Do you mind? Can you say anything about the response from big investors or. Big stakeholders.

Anders Tullgren
43:41 - 43:59

No comments, except that we are, as we always do, trying to have as good a dialogue as possible with larger shareholders and with all shareholders. And we're doing that in webcasts like the one we're currently holding.

Unknown
44:00 - 44:00

Yes.

Martin Åmark
44:01 - 44:06

And then I think, where do you see Xbrane in a year.

Unknown
44:10 - 44:11

Anyone?

Unknown
44:15 - 44:17

Hey. Yes, I can.

Anders Tullgren
44:17 - 44:55

I can start on that one. Well, in a year's time, my absolute ambition is that we would have, if we stick to the subject of this particular webcast, resolved these outstanding issues and have our biosimilar candidate approved in the US and also, of course, have a commercialization partner tied up and either have launched or are just about to launch the product in the US. That is my ambition and hope. Yes.

Martin Åmark
44:58 - 45:16

Going back to biosimilar sales in Europe, there's a question around monitoring the sales on a more monthly basis and reporting that to the market. Do you want to say anything about our collaboration with data and how those reports work?

Unknown
45:19 - 45:19

Yes.

Anders Tullgren
45:20 - 45:44

So, we are having a rather close collaboration with a startup and getting, I think, appropriate information with regards to the sales process, but we have no intentions of reporting to the market on sales in Europe other than in our quarterly reports on a quarterly basis.

Unknown
45:45 - 45:45

Yes.

Martin Åmark
45:47 - 46:21

And I think with that, we have covered the themes in the questions, as far as I can tell. So, is there anyone who wants to pose a question? Some last questions, so please do. Okay. Uh, there are no further questions. So, Martin, the final word. Anders.

Anders Tullgren
46:23 - 46:49

Yeah, I know, I can just say, as we've talked about in this call, we're disappointed, of course, of having received this Complete Response Letter. But we're now committed to work together with the FDA and with our contract manufacturers to resolve these issues as swiftly as possible and get towards resubmission and eventual approval of the product in the US.

Unknown
46:50 - 46:50

Yeah.

Unknown
46:51 - 47:48

Yeah. And also from my side, Anders is here, I can just say that we're working very hard on this issue. We're working with the FDA, but we also have to remember that we have four other big opportunities, which we are also working on in parallel, and that we are working very closely together from the board with the management and also with our partners, to resolve these issues and also working on the future of Xbrane. And we welcome all the feedback and all the interest and all the questions. And, uh, we are also continuously moving forward, we'd like to have very close contact. And as we have more information coming available, we will of course also keep you informed. All of you. So thank you for participating today. And thanks for all the questions that you posed. So I think with that, Anette, I think we can close today's call.

Martin Åmark
47:48 - 48:04

Yes. So thank you very much. Everybody listening in, as always, in case you have any further questions, then please don't hesitate to come back to us through email to Martin or myself. So thank you very much.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…